Diamonds and Dogs


Mylan (MYL) getting a boost. The generic drug maker is up a percent not far from its monthly high after announcing the launch of a generic drug version of Zovia, used by women to prevent pregnancy. 2016 is a year Mylan would like to forget as the stock and company got battered after politicians exposed the dramatic price hike for their popular life-saving drug, the epipen. Mylan currently has more than 240 drugs pending FDA approval and trades for only 7 times earnings.  Hopefully 2017 will be a better year for Mylan.

Ionis Pharmaceuticals (IONS) has been on a roller coaster ride this year. The biotech company along with partner, Biogen received FDA approval for Spinraza, the first treatment in the U.S. for spinal muscular atrophy particularly in children and adolescents. That's the good news. However, Ionis stock is lower by 3.5% on concerns for pricing on the drug and treatment. An analyst estimates there are about 1,700 patients who could start treatment in 2017, but at a cost of around $400,000 for the first year of treatment (the dosing schedule involves more of the drug being used initially), and $200,000 per patient in year two and beyond.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.